A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B

Authors
Category Primary study
JournalBlood
Year 2014
This article has no abstract
Epistemonikos ID: 8d3cc2dd61561796fad865386c067576bec621f9
First added on: Feb 19, 2025